summit trial tirzepatide Another "Positive" Heart Failure that Falls Short SUMMIT trial results presented at
Pay in 4 interest-free payments of $5.83 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Live Spec
SUMMIT trial results presented at #AHA24 show tirzepatide reduced the risk of worsening heart failure events and improved quality of life in patients with #HFpEF and obesity. Cardiologists now have an ever expanding Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity In the SUMMIT trial, researchers examined cardiovascular outcomes of treatment with tirzepatide in patients with heart failure with preserved ejection fraction and obesity. Full trial results and Plain Language Summary: https: nej.md 4hRGaTY Medthreads Tirzepatide made headlines for weight loss. But that's not why longevity doctors are paying attention. As a dual GIP GLP 1 receptor agonist, it works on pathways that go far beyond metabolism. The data
Store: finou-maps.com · Domain: finou-maps.com


























